AstraZeneca PLC (AZN)vsNovocure Ltd (NVCR)
AZN
AstraZeneca PLC
$185.95
-1.94%
HEALTHCARE · Cap: $282.69B
NVCR
Novocure Ltd
$17.16
-4.61%
HEALTHCARE · Cap: $2.06B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 8862% more annual revenue ($60.44B vs $674.41M). AZN leads profitability with a 17.2% profit margin vs -25.7%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
NVCR
Avoid29
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+8.2%
Fair Value
$194.77
Current Price
$185.95
$8.82 discount
Margin of Safety
+81.5%
Fair Value
$56.90
Current Price
$17.16
$39.74 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
No standout strengths identified
Areas to Watch
Moderate valuation
Distress zone — elevated risk
Weak financial health signals
ROE of -52.3% — below average capital efficiency
Earnings declined 6.0%
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : NVCR
Revenue growth of 12.3% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : NVCR
The primary concerns for NVCR are Piotroski F-Score, Return on Equity, EPS Growth.
Key Dynamics to Monitor
AZN profiles as a mature stock while NVCR is a turnaround play — different risk/reward profiles.
NVCR carries more volatility with a beta of 0.92 — expect wider price swings.
AZN is growing revenue faster at 12.5% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 29/100), backed by strong 17.2% margins and 12.5% revenue growth. NVCR offers better value entry with a 81.5% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Novocure Ltd
HEALTHCARE · MEDICAL DEVICES · USA
NovoCure Limited, an oncology company, is engaged in the development, manufacture and marketing of Optune for the treatment of a variety of solid tumors. The company is headquartered in Saint Helier, Jersey.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?